These highlights do not include all the information needed to use TYENNE safely and effectively. See full prescribing information for TYENNE. TYENNE® (tocilizumab-aazg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2024TYENNE® (tocilizumab-aazg) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of TYENNE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration) described in its Full Prescribing Information. to ACTEMRA® (tocilizumab).

Patient Home

Welcome to Health Vidya. Discover trusted care and your own health — all in one place.

These highlights do not include all the information needed to use TYENNE safely and effectively. See full prescribing information for TYENNE. TYENNE® (tocilizumab-aazg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2024TYENNE® (tocilizumab-aazg) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of TYENNE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration) described in its Full Prescribing Information. to ACTEMRA® (tocilizumab).

Medication label

Why this: Advisory · dailymed-prescription

TYENNE® (tocilizumab-aazg) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). TYENNE® (tocilizumab-aazg) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. TYENNE® (tocilizumab-aazg) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. TYENNE® (tocilizumab-aazg) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. TYENNE® (tocilizumab-aazg) is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older. TYENNE® (tocilizumab-aazg) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult and pediatric patients aged 2 years and older who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

generic_name: tocilizumab-aazg
product_names: Tocilizumab-aazg
ndc: 65219-586, 65219-584, 65219-586-04, 65219-584-01
group: drugs
license: us-gov-pd
attribution: Courtesy of the National Library of Medicine
reviewed: 2026-09-18
language: en